Business Context and Reporting Period
Advanced Biomed Inc. (ADVB), a Nevada corporation and emerging growth company, filed this Form 8-K on July 14, 2026. The report addresses the termination of a material definitive agreement entered into on June 6, 2025.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the termination of a financing agreement.
Material Changes
- Termination of Purchase Agreement: The Company terminated a $25,000,000 At-The-Market (ATM) purchase agreement with Helena Global Investment Opportunities I Ltd.
- Effective Date: The termination becomes effective on July 21, 2026, following the required five trading days' notice.
- Capital Raised: No shares of Common Stock were issued or sold to the Investor under the agreement, other than the required Commitment Fee Shares.
- Conditions Met: The Company confirmed there were no outstanding Advance Notices and that all amounts owed, including Commitment Fee Shares, were fully paid.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclaimer regarding the Purchase Agreement. The termination was executed pursuant to Section 11.02(b) of the agreement, which allows the Company to terminate at its sole discretion provided specific conditions are met.
Investor Verification Checklist
- Verify the effective date of the termination (July 21, 2026) to confirm the agreement is no longer active.
- Confirm that no shares were issued under the $25,000,000 facility, indicating the Company did not utilize this capital source.
- Review the June 6, 2025 Form 6-K (Exhibit 99.1) for the full text of the terminated Purchase Agreement.
- Check subsequent filings for any new financing arrangements to replace the terminated facility.